Rufinamide Tablets News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rufinamide tablets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rufinamide Tablets Today - Breaking & Trending Today

Alembic, Aurobindo Recall Drugs In US Market

Alembic, Aurobindo Recall Drugs In US Market
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.

United States , Aurobindo Pharma , Alembic Pharmaceuticals , Aurobindo Pharma United States Inc , Alembic Pharmaceuticals Inc , Drug Administration , Enforcement Report , Tobramycin Ophthalmic Solution , Ophthalmic Solution , Jersey Based Alembic Pharmaceuticals Inc , Degradation Specifications , Rufinamide Tablets , Pharma United States Inc ,

Alembic, Aurobindo recall drugs in US market

Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide Tablets, in both 200 mg and 400 mg doses, due to cGMP (current good manufacturing practice) deviations, USFDA said. The batch was released prior to approval. Rufinamide tablets are used to treat seizure disorders. ....

New Delhi , United States , Aurobindo Pharma , Drug Administration , Alembic Pharmaceuticals , Aurobindo Pharma United States Inc , Alembic Pharmaceuticals Inc , Enforcement Report , Tobramycin Ophthalmic Solution , Ophthalmic Solution , Jersey Based Alembic Pharmaceuticals Inc , Degradation Specifications , Rufinamide Tablets , Pharma United States Inc , Us Market ,

Lupin launches Rufinamide Tablets USP in the United States

Global pharma major Lupin Limited today announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel® Tablets, 200 mg and 400 mg, of Eisai Inc. ....

United States , Lupin Limited , Eisai Inc , Rufinamide Tablets ,

Barometers trade almost flat; breadth turns weak

The key barometers hovered near the flat line in early afternoon trade. Metal shares tumbled while autos and FMCG shares bucked weak market trend.
At 12:20 IST, the barometer index, the S&P BSE Sensex, rose 6.05 points or 0.01% at 51,943.49. The Nifty 50 index lost 15.25 points or 0.10% at 15,567.55. The Nifty pared losses after hitting the day s low of 15,528.30 in early afternoon trade.
In the broader market, the S&P BSE Mid-Cap index fell 0.39% while the S&P BSE Small-Cap index slipped 0.51%.
The market breadth was weak. On the BSE, 1,112 shares rose and 1,857 shares fell. A total of 124 shares were unchanged.
Derivatives:
The NSE s India VIX, a gauge of market s expectation of volatility over the near term, jumped 5.92% to 17.89. The Nifty 29 July 2021 futures were trading at 15,564.45, at a discount of 3.10 points as compared with the spot at 15,567.55. ....

United States , National Income , Sunteck Realty , Union Health Ministry , Eisai Inc , Ministry Of Health , Glenmark Pharmaceuticals , Hemisphere Properties India , National Statistical Office On , Nifty Realty , Index Of Eight Core Industries , Gross Domestic Product , National Statistical Office , Fiscal Deficit , Controller General , Eight Core Industries , India Manufacturing Purchasing Manager Index , Pollyanna De Lima , Economics Associate Director , Family Welfare , Union Health , Bulls Real Estate , Rufinamide Tablets , Jubilant Pharma , Jubilant Pharmova , Essel Propack ,

Glenmark Pharmaceuticals launches Rufinamide Tablets

Glenmark Pharmaceuticals (Glenmark) has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel1 Tablets, 200 mg and 400 mg of Eisai, Inc.
Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on 16 May 2016.
According to IQVIATM sales data for the 12 month period ending April 2021, the Banzel Tablets, 200 mg and 400 mg market achieved annual sales of approximately $285.3 million.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) ....

Glenmark Pharmaceuticals , Eisai Inc , Rufinamide Tablets , Banzel Tablets , Capital Market , Branches Of Biology , Life Sciences , Magnesium In Biology , Generic Pharmaceuticals , Harmaceuticals Nec , Glenmark Pharmaceuticals , Ufinamide Tablets Usp , க்ளேண்மர்க் மருந்துகள் , ேசை இன்க் , மூலதனம் சந்தை , கிளைகள் ஆஃப் உயிரியல் ,